Aethlon Medical (AEMD) Set to Announce Earnings on Wednesday

Aethlon Medical (NASDAQ:AEMD) is anticipated to announce its Q2 2027 resultson Wednesday, November 11th. Analysts expect Aethlon Medical to post earnings of ($2.91) per share for the quarter. Investors can find conference call details on the company’s upcoming Q2 2027 earnings report for the latest details on the call scheduled for Wednesday, November 11, 2026 at 4:30 PM ET.

Aethlon Medical (NASDAQ:AEMD) last issued its quarterly earnings data on Thursday, August 13th. The medical equipment provider reported ($4.02) EPS for the quarter, missing analysts’ consensus estimates of ($3.92) by ($0.10). On average, analysts expect Aethlon Medical to post ($5.74) EPS for the current fiscal year and ($0.57) EPS for the next fiscal year.

Aethlon Medical Price Performance

Shares of NASDAQ AEMD opened at $5.69 on Wednesday. The firm has a market capitalization of $4.04 million, a PE ratio of -0.16 and a beta of 1.27. Aethlon Medical has a 1-year low of $1.41 and a 1-year high of $25.66. The business’s fifty day moving average price is $4.59 and its two-hundred day moving average price is $7.72.

Analyst Upgrades and Downgrades

Several equities analysts have recently commented on the stock. HC Wainwright restated a “neutral” rating on shares of Aethlon Medical in a research report on Friday, September 18th. Wall Street Zen upgraded shares of Aethlon Medical to a “sell” rating in a research report on Saturday, October 17th. Finally, Weiss Ratings reissued a “sell (e+)” rating on shares of Aethlon Medical in a research note on Thursday, October 15th. One equities research analyst has rated the stock with a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, the company presently has a consensus rating of “Reduce” and an average target price of $1.50.

Aethlon Medical Company Profile

Aethlon Medical, Inc is a biotechnology and medical-device company focused on developing extracorporeal blood filtration technologies for life-threatening diseases. The company’s lead product candidate, the Hemopurifier, is designed to selectively remove harmful substances from the bloodstream, including cancer-promoting exosomes and certain viral particles.

The Hemopurifier is intended to be used with standard dialysis or blood-circulation equipment and is being investigated for potential applications in oncology and infectious disease.